<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Clinical trials on medicinal products for human use (A7-0208/2013 - Glenis Willmott) - Thursday, 3 April 2014</title><meta name="title" content="Verbatim report of proceedings - Clinical trials on medicinal products for human use (A7-0208/2013 - Glenis Willmott) - Thursday, 3 April 2014" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2014 - Source: European Parliament" /><meta name="available" content="03-04-2014" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Clinical trials on medicinal products for human use (A7-0208/2013 - Glenis Willmott) - Thursday, 3 April 2014" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2014-04-03-ITM-009-17_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-17_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-03-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-03-ITM-009-16_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03-ITM-009-16_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03-ITM-009-18_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2014-04-03-ITM-009-18_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-03_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/0192(COD)">2012/0192(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0208/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0208_EN.html" class="ring_ref_link">A7-0208/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-7-2014-04-02-ITM-015_EN.html" class="ring_ref_link">PV 02/04/2014 - 15</a><br />
                        <a href="/doceo/document/CRE-7-2014-04-02-ITM-015_EN.html" class="ring_ref_link">CRE 02/04/2014 - 15</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2014-04-02-ITM-018-18_EN.html" class="ring_ref_link">PV 02/04/2014 - 18.18</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2014-0273_EN.html" class="ring_ref_link">P7_TA(2014)0273</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Thursday, 3 April 2014 - Brussels</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 9.17. Clinical trials on medicinal products for human use (<a href="/doceo/document/A-7-2013-0208_EN.html">A7-0208/2013</a> - Glenis Willmott) </td></tr></table>
<a name="4-223-812"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Γραπτές αιτιολογήσεις ψήφου</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-859"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118860.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claudette Abela Baldacchino (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> Pharmaceutical companies and academic researchers will have to post the results of all their European clinical trials in a publicly-accessible database, under a draft law already informally agreed with EU ministers and now passed by Parliament. The law also facilitates cross-border cooperation to make clinical trials larger, more viable and more reliable, which should in turn boost efforts to develop special treatments, e.g. for rare diseases.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-072"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Aprovo o presente relatório tomando em consideração que todos os intervenientes estão amplamente de acordo que a legislação em vigor relativa a ensaios clínicos necessita de uma revisão urgente. Tem havido um declínio acentuado no número de ensaios clínicos realizados na Europa nos últimos anos, o que se deve, pelo menos em parte, a algumas medidas que constam da Diretiva relativa aos ensaios clínicos. Além das graves consequências económicas, este facto impede igualmente o avanço da medicina em detrimento dos doentes. A Europa tem de ser competitiva e um local atrativo para as empresas farmacêuticas desenvolverem investigação, fomentando ao mesmo tempo a investigação académica e incentivando a investigação de medicamentos para doenças raras. Simultaneamente, a Europa deve ser um líder mundial em termos de segurança dos doentes e de transparência, no interesse da confiança do público e do rigor científico. Um dos principais problemas da atual diretiva é precisamente a sua forma jurídica, ou seja, o facto de ser uma diretiva, sendo necessário uma abordagem diferente que permita melhores resultados em termos globais.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-274"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96862.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sophie Auconie (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur du règlement relatif aux essais cliniques qui remplace la précédente directive de 2001. L'ancienne législation européenne était dépassée et les conséquences négatives nombreuses comme des délais d'approbation interminables, une augmentation des coûts de réalisation, la diminution des demandes d'autorisation ou encore des délocalisations. Ce texte permettra une harmonisation des règles offrant aux chercheurs une procédure d'autorisation claire et centralisée et des essais cliniques multinationaux plus simples à mettre en place.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-578"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113883.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Erik Bánki (PPE), </span></span>  <span class="italic">írásban</span><span class="bold">. -</span> Az emberi felhasználásra szánt gyógyszerek klinikai vizsgálatait szabályozó rendelet régi hiányosságot pótol az Európai Unióban, mely reményeink szerint hozzájárul az engedélyezési eljárások felgyorsulásához, ésszerűsítéséhez, ezáltal segítve új, hatékony készítmények kifejlesztését. Fontos, hogy a javaslatba új elemként bekerültek az etikai kérdések is, tagállami hatáskörben hagyva az etikai bizottságok részvételének részletes szabályozását. Magyar részről kifejezetten fontosnak tartom továbbá, hogy a kiszolgáltatott csoportok – kiskorúak, cselekvőképességükben korlátozottak, terhes nők és más, sajátos helyzetű csoportok – védelme szélesebb lett, hiszen hazánkban eleve erősebb ez a szabályozás, és ezt meg is tudtuk tartani. Mindezek alapján támogattam szavazatommal a jelentést.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-882"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96814.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Băsescu (PPE), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Uniunea Europeană are un potențial enorm de exploatat în domeniul medical. Dispunem de experți, infrastructură și fonduri suficiente pentru a putea excela la nivel mondial. Dar pentru a atrage investiții externe și pentru a stimula inovația avem nevoie de o legislație unitară și de cât mai puțină birocrație. Pe de o parte, trebuie accelerate și simplificate procedurile de autorizare și raportare ale studiilor clinice. Însă, pe de altă parte, trebuie menținute cele mai ridicate standarde de siguranță și transparență pentru pacienți. </p>
<p class="contents">În altă ordine de idei, constat cu regret că România se află la coada clasamentului în Europa la capitolul investițiilor în cercetare și dezvoltare în medicină. Sper ca guvernul Ponta să realizeze că beneficiile inovației în medicină sunt majore: atât asupra pacienților, cât și ca impact economic la nivelul țării.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-894"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28214.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Bennahmias (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Bien que la recherche scientifique notamment à vocation curative doive être encouragée, il est cependant impératif que celle-ci réponde à des précautions précises afin d'éviter toute pratique pouvant s'apparenter à la marchandisation de l'humain.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-073"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118709.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Fabrizio Bertot (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> La presente relazione nasce dalla necessità ormai forte di modificare la legislazione vigente in materia di sperimentazioni cliniche alla luce della riduzione considerevole del numero delle sperimentazioni cliniche condotte in Europa riconducibile sovente ad alcuni dei provvedimenti della direttiva in materia di sperimentazioni cliniche. Ho votato a favore della relazione sulle sperimentazioni in linea con il PPE, perché credo sia opportuno compiere dei passi avanti in questo ambito per progredire con la scienza medica al fine di salvaguardare al meglio i pazienti e, al contempo, arginare gli effetti economici pesanti che una fase di stallo potrebbe comportare. A tal proposito l'UE deve puntare a un ruolo di pioniere nella promozione della ricerca e dello sviluppo di farmaci per le malattie rare: in tal modo sarà possibile rendersi più interessanti per le società farmaceutiche, nonché essere all'avanguardia a livello mondiale in materia di sicurezza dei pazienti e trasparenza in modo da garantire la fiducia dell'opinione pubblica e la validità della scienza. Accolgo pertanto gli emendamenti presentati, in quanto ritengo che vadano nella giusta direzione al fine di migliorare la normativa vigente e renderla più solida in virtù delle esigenze attuali e delle prospettive future.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-897"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97198.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mara Bizzotto (EFD), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Ho votato a favore di questa relazione che affronta un tema molto delicato in modo equilibrato e concreto.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-901"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29074.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vito Bonsignore (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> La relazione costituisce un test della nostra capacità di applicare coerentemente il set di valori europei a fronte di dinamiche del sistema produttivo globale, in un delicato equilibrio tra irrinunciabili diritti della persona e della possibilità (ovvero della naturale predisposizione) del mercato ad autoregolarsi. Da un lato, in questa legislatura abbiamo lavorato sul brevetto europeo, e sarebbe inconcepibile trascurare il danno prodotto al settore farmaceutico europeo da una legislazione bisognosa di urgente adeguamento; dall'altro, lo spostamento delle attività di sperimentazione nei Paesi terzi solleva genuini interrogativi in ambito etico e può fomentare una certa subcultura complottista, ostile al modello occidentale e al libero mercato. Le raccomandazioni e le modifiche introdotte dal relatore intervengono con ponderato equilibrio su una serie di nodi importanti con soluzioni condivisibili: dalle misure di pubblicità e trasparenza dei test all'estensione degli standard europei alle sperimentazioni nei PVS, dall'incontro dei comitati etici da cui possa scaturire una cultura d'impresa del settore di respiro europeo al sostegno pubblico dei costi assicurativi che costituiscono un freno alle attività di sperimentazione avanzata, e quindi in ultima istanza potrebbero anche ritardare sviluppi di grande rilievo per la qualità della vita degli europei. Pertanto esprimo un voto favorevole.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-903"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113597.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Minodora Cliveti (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Într-un trial clinic siguranța, drepturile, sănătatea și bunăstarea subiecților ar trebui protejate și datele generate ar trebui să fie relevante, fiabile, robuste și să reflecte diversitatea populației în ceea ce privește echilibrul referitor la vârstă și la gen. Interesele participanților ar trebui să aibă întotdeauna prioritate față de alte interese. Regulamentul va garanta coerența punerii în aplicare a legislației în cadrul UE. Acest lucru va fi benefic în special pentru cei care efectuează cercetări în domeniul bolilor rare, având în vedere că numărul redus al pacienților vizați face ca studiile transfrontaliere să fie indispensabile. </p>
<p class="contents">Totodată, este importantă crearea de sisteme naționale de indemnizare. În prezent, costurile de asigurare legate de anumite trialuri clinice sunt astronomice și pot descuraja numeroși sponsori să realizeze aceste trialuri. Adesea, trialurile clinice academice, în special cele privind bolile rare, sunt cele excluse de pe piață din cauza costului prea ridicat al asigurărilor. Aceste tipuri de trialuri trebuie încurajate și susținute, motiv pentru care este esențial să se prevadă un sistem de indemnizare. În prezent, cea mai mare parte a fondurilor publice investite în cercetarea medicală este dedicată cheltuielilor de asigurare. Costurile de funcționare ale unui sistem de indemnizare ar fi relativ scăzute pentru statele membre.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-904"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/95281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vasilica Viorica Dăncilă (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Având în vedere că trialurile clinice efectuate într-un singur stat membru sunt, de asemenea, indispensabile cercetării clinice europene, procedura prevăzută de prezentul regulament ar trebui să acopere și aceste trialuri clinice. Consider că, pentru aceste trialuri clinice, dosarul de cerere ar trebui să fie transmis, de asemenea, prin intermediul portalului unic european.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-074"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/72775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rachida Dati (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Ce texte vise à modifier la législation relative aux essais cliniques de médicaments à usage humain afin de renforcer la santé publique tout en encourageant la recherche. Il est fondamental de promouvoir la recherche clinique en Europe, notamment par une simplification et une clarification des procédures. La compétitivité de la recherche clinique en Europe est donc relancée, alors que le nombre d'essais cliniques menés en Europe ces dernières années était en diminution.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-281"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96826.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tamás Deutsch (PPE), </span></span>  <span class="italic">írásban</span><span class="bold">. -</span> Az Európai Számvevőszék elkészítette a 2012-es pénzügyi évre vonatkozó éves jelentését, melyet ismertetett az Európai Parlament plénuma előtt, majd a Költségvetési Ellenőrző Bizottságban is. A jelentés bemutatását követően a 2012. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az ügynökségek költségvetése végrehajtására vonatkozó pénzügyi ellenőrzését. A szakbizottság elsődleges feladata a közösségi költségvetés végrehajtásának szabályosságát és hatékonyságát biztosítani, ellenőrizni. Az Energiaszabályozók Együttműködési Ügynökségének 2012-es gazdálkodásával kapcsolatban a zárszámadási jelentés megállapítja, hogy a pénzügyi átvilágítás rendben lezajlott, és a vizsgálat során hiányosságokat nem tapasztaltak. A szakbizottság március 17-i ülésén a mentesítés megadásáról, és a 2012-es számlák lezárásáról döntött. A szakbizottsági szavazáson és az április 3-i plenáris szavazáson is a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-905"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4347.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Christine De Veyrac (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur de ce texte qui permet aux États membres de s'appuyer sur un seul et même texte pour évaluer les demandes d'autorisation d'essai clinique. Cette plus grande transparence s'inscrit dans la volonté de protéger les participants en leur garantissant un consentement libre et éclairé. Je me félicite aussi qu'un chapitre concernant la protection des données à caractère personnel soit prévu dans ce règlement.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-035"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96951.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diane Dodds (NI), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I welcome the focus of this Report toward setting guidelines for safe and effective clinical trials of medicinal products. Investing in our health research infrastructure is crucial to ensuring that the quality of patient services, and processes used to prevent, diagnose and treat disease, continues to improve in a medical environment with many challenges. In my own constituency, Northern Ireland, a new medical research centre in Belfast worth GBP 4 million was opened in September 2013. It is part of a joint venture between academic institutions, the Belfast Health and Social Care Trust and Public Health Agency. This resource will be key to gaining new knowledge which can then be applied and put into practice with great benefits for people across the Province. </p>
<p class="contents">The Committee’s Report would strengthen the principle of informed consent for clinical trials. It would also ensure research proposals are effectively assessed, and that they compel better disclosure of trial results – negative or positive. Trials which may result in inheritable changes to a person would be banned. This transparency and foresight in relation to the preparation of, and consequences stemming from, clinical trials is vital to ensure safety and good practice. I therefore welcome the proposals.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-252"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96977.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diogo Feio (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Esta Diretiva versa sobre as regras a aplicar em todos os ensaios clínicos para uso humano que decorram na União Europeia. Vários são os princípios elencados e que devem sempre ser observados, sem exceção, para aprovação de um ensaio clinico. A necessidade de aprovação por uma Comissão de Ética é um requisito <span class="italic">sine qua non</span>, bem como a participação de grupos de risco, como grávidas, estará sujeita a regras mais restritas. Assim, gostaria de felicitar todo o trabalho desenvolvido que vem definir regras e parâmetros europeus rigorosos nesta matéria.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-361"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96993.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lorenzo Fontana (EFD), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Esiste ampio consenso tra tutte le parti interessate sull'urgente necessità di riformare la legislazione vigente in materia di sperimentazioni cliniche. Negli ultimi anni si è assistito a un notevole calo del numero delle sperimentazioni cliniche condotte in Europa, dovuto, perlomeno in parte, ad alcuni dei provvedimenti negativi della direttiva. Ritengo che le modifiche qui proposte siano necessarie per migliorare la disciplina. Per questo, manifesto voto favorevole.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-470"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102886.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ildikó Gáll-Pelcz (PPE), </span></span>  <span class="italic">írásban</span><span class="bold">. -</span> Üdvözlendőnek találtam és pozitív szavazatommal támogattam a jelentést, ugyanis megegyező álláspontot képviselek a klinikai vizsgálatokról szóló jelenlegi jogszabály tekintetében. Úgy gondolom, hogy sürgős felülvizsgálatra szorul, annál fogva, hogy az elmúlt néhány év során komoly csökkenés állt be az Európában végrehajtott klinikai vizsgálatok számában, ami nemcsak súlyos gazdasági következményekkel jár, hanem az orvostudomány haladását is gátolja a betegek kárára. Üdvözlendőnek tartom az előadó által megfogalmazott prioritásokat, miszerint a betegek magas színvonalú gondozásának és ellátásának fenntartását az Unióban biztosítani kell, és ezzel egy időben ösztönözni a tudományos kutatásokat és az innovációt. Kiemelten fontosnak tartom felhívni a figyelmet arra is, hogy figyelembe véve a jelenlegi gazdasági válságot, nem szabad pénzt pazarolni olyan gyógyszerekre, amelyek nem hatásosak, és az embereknek képesnek kell lenniük arra, hogy az egészségükkel kapcsolatban tájékozottan hozzanak döntéseket. Európának versenyképesnek kell lennie, és vonzóvá kell tennie a gyógyszeripari vállalatok számára a kutatások itt történő elvégzését, a tudományos kutatás segítése és a ritka betegségek gyógyszereire irányuló fejlesztés ösztönzése mellett. Meggyőződésem, hogy a fentebb megfogalmazott célok elérése érdekében a bürokrácia csökkentése és az átláthatóság növelése is elengedhetetlenül fontos tényezők.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-524"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2025.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Grossetête (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur de ce règlement qui comporte des avancées concrètes pour faciliter la mise en œuvre des essais cliniques portant sur des médicaments à usage humain en Europe tout en garantissant les droits des personnes participant à ces recherches. Il était en effet essentiel de réviser cette directive de 2001 car la complexité des mesures de mise en œuvre d'un essai clinique est devenue telle que les investigateurs préfèrent se tourner vers d'autres pays aux règlements plus souples. </p>
<p class="contents">Les nouvelles règles permettront non seulement d'encourager la réalisation d'essais cliniques portant sur le médicament en Europe grâce à la simplification administrative adoptée mais aussi de garantir une plus grande transparence des résultats des essais. Des procédures de notification simplifiée éviteront aux chercheurs de devoir présenter à plusieurs organismes des informations en grande partie identiques sur l'essai clinique envisagé. Un dossier de demande d'autorisation unique pour tout essai, national ou multinational, sera déposé sur un portail de l'Union européenne par le promoteur et un État membre rapporteur sera désigné afin d'évaluer les aspects scientifiques et méthodologiques de la recherche. </p>
<p class="contents">Ce nouveau règlement donnera l'assurance pour les patients européens de pouvoir bénéficier des meilleurs soins et des médicaments les plus récents.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-688"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/37448.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Eduard-Raul Hellvig (ALDE), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Progresul în medicină este condiționat de inovație. Pentru a asigura accesul pacienților la medicamente inovatoare și eficiente este, în mod evident, nevoie de un cadru legislativ care să încurajeze industria farmaceutică să investească în cercetare și inovare în Europa și să introducă pe piață noi tratamente. </p>
<p class="contents">Acordul asupra modernizării legislației privind studiile clinice este o veste bună atât pentru pacienți, cât și pentru competitivitatea industriei farmaceutice europene. Până acum, numărul studiilor clinice a fost în continuă scădere, în parte din cauza obstacolelor administrative generate de directiva din 2001, în special în cazul studiilor clinice multinaționale, extrem de importante în cazul tratamentelor pentru bolile rare. Noul regulament adoptat astăzi va încuraja studiile clinice în UE, oferind proceduri comune mai rapide și mai simple pentru aprobarea acestora. În ceea ce privește termenele pentru aprobare, acestea ar fi putut fi mai ambițioase, însă chiar și cele prevăzute de acord sunt un progres față de situația actuală. </p>
<p class="contents">De asemenea, acest text aduce mai multă transparență a rezultatelor studiilor clinice, o protecție sporită a subiecților și un sistem de raportare a aspectelor legate de siguranța medicamentelor. Toate acestea vor face UE mai atractivă pentru studiile clinice, crescând totodată calitatea rezultatelor și asigurând încrederea în acest sistem.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-715"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96884.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Juvin (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur du rapport de ma collègue Glenis Willmott sur les essais cliniques de médicaments à usage humain. Ce texte, auquel j'ai contribué en tant que rapporteur du groupe PPE, est une avancée majeure pour la recherche clinique européenne, qui subissait les conséquences catastrophiques d'une directive de 2001. </p>
<p class="contents">Avec l'explosion des coûts et des délais d'autorisation, le nombre de demande d'autorisation d'essais cliniques dans l'Union s'est effondré, au profit des États-Unis et des pays émergents. Ce rapport vise à rétablir la compétitivité de la recherche clinique européenne tout en consacrant des mesures de transparence. Les procédures d'autorisation des essais cliniques sont ainsi harmonisées et simplifiées, et garantissent d'obtenir une réponse dans des délais courts. Les citoyens auront accès à une base de données européenne centralisant les informations sur les essais cliniques autorisés dans l'Union européenne. Les promoteurs d'essais cliniques auront l'obligation de publier sur cette base de données des résumés des résultats des essais effectués. La recherche clinique européenne va donc enfin retrouver le chemin vers la compétitivité et favoriser l'arrivée rapide sur le marché de traitements innovants à destination des patients. </p>
<p class="contents">Je me réjouis de l'adoption de ce rapport à une très large majorité: 594 voix pour, 17 voix contre et 13 abstentions.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-756"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96816.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Giovanni La Via (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> L'approvazione della direttiva 2001/20/CE ha segnato una svolta importante nello sviluppo delle norme per lo svolgimento della sperimentazione clinica, sia a livello europeo sia a livello internazionale. Bisogna garantire che nell'Unione si mantengano norme rigorose a livello di assistenza e cura dei pazienti, promuovendo al contempo la ricerca scientifica e l'innovazione, attraverso l'accesso del pubblico ai dati, sotto forma di relazione completa sulla sperimentazione clinica. È comunque necessaria un'armonizzazione e un'attenta valutazione del quadro giuridico esistente per evitare difficoltà nella promozione della sperimentazione clinica nei diversi Stati membri.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-797"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/105849.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Agnès Le Brun (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Mercredi 2 avril, j'ai voté en faveur de mesures visant à simplifier et à rendre plus sûr et plus transparent le cadre législatif pour les essais cliniques. </p>
<p class="contents">Les demandes d'autorisation relatives à des essais cliniques seront simplifiées, alors que plus de 4[nbsp ]400 demandes sont déposées chaque année en Europe. Nous avons fixé des délais d'approbation afin d'éviter le blocage d'essais cliniques par des lenteurs administratives. Nous avons également accru la transparence et l'accès à l'information grâce à un portail internet sur lequel tous les résultats des essais, ainsi que les autorisations de mise sur le marché et les décisions de retrait du marché devront être publiées. Il s'agit d'une avancée particulièrement essentielle. </p>
<p class="contents">Enfin, nous avons harmonisé les règles d'autorisation et d'évaluation des essais cliniques afin de faciliter la réalisation d'essais cliniques transfrontaliers. Ces nouvelles règles favoriseront la recherche dans le domaine des maladies rares, pour lesquelles le nombre de patients est insuffisant dans un seul pays européen pour initier des essais cliniques au regard des coûts générés. </p>
<p class="contents">Les mesures adoptées par le Parlement européen permettront d'économiser plus de quatre milliards d'euros entre 2014 et 2020.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-824"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Ce rapport vise soi-disant à renforcer la coopération scientifique au sein de l'Union et à permettre d'accroître les connaissances dans le domaine de la santé publique. Il part du constat de la chute de 25[nbsp ]% des essais cliniques en Europe et des conséquences de ce frein dans la recherche de traitements médicaux. Le règlement vise à mieux définir et encadrer les essais cliniques et également à mieux protéger et prendre en compte les patients qui consentent à y participer. </p>
<p class="contents">Mais une fois de plus, le point de vue économique et financier prime sur la recherche. Il s'agit donc de diminuer les délais, de simplifier les démarches "bureaucratiques", c'est-à-dire d'augmenter les cadences et de supprimer des postes. Tout cela dans le but de diminuer les coûts pour faire revenir les promoteurs privés partis faire leurs tests en dehors de l'UE. Ces mêmes promoteurs pratiquent en priorité les essais cliniques rentables, excluant du coup ceux pour les maladies rares. De toute manière, la baisse des crédits relatifs à la recherche publique, liée à la politique d'austérité menée dans toute l'Europe, n'est absolument pas remise en question. Dans ce cadre, je m'abstiens.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-865"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118859.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Roberta Metsola (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I support this report, which calls for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use because I agree that the current legislation on clinical trials urgently needs to be revised. Europe should be a world leader in both patient safety and transparency, in the interest of public trust and good science, and I believe that this regulation will help the European Union in achieving those goals.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-843"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28407.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Willy Meyer (GUE/NGL), </span></span>  <span class="italic">por escrito</span><span class="bold">. -</span> En el presente informe no he podido votar a favor de la Decisión del Parlamento de aprobar la gestión del presupuesto de la Agencia para la Cooperación de los Reguladores de la Energía para el ejercicio 2012, pero sí a favor de la consiguiente Resolución. Mediante el presente informe, el Parlamento Europeo ejerce el derecho de supervisar las cuentas de las agencias de la Unión Europea. En este caso aprueba la gestión de la citada Agencia, y como no estoy de acuerdo con ello no he votado a favor. Sin embargo, la Resolución recoge de forma completa los principales puntos destacados de la citada gestión durante el ejercicio 2012. Es por todo esto por lo que no he votado a favor de la Decisión de aprobación de la gestión pero sí a favor de la Resolución.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-174"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28407.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Willy Meyer (GUE/NGL), </span></span>  <span class="italic">por escrito</span><span class="bold">. -</span> He votado a favor del presente informe debido a que supone una mejora en la regulación de los ensayos clínicos en la Unión Europea, de manera que se permita un funcionamiento más transparente de este tipo de pruebas de los medicamentos de uso humano. Este informe introduce la consideración de que los ensayos clínicos de este tipo de medicamentos no pueden ser considerados como secreto comercial, puesto que tienen que ver con la salud humana. Además, el informe insta a la creación de una base de datos europea con toda la información relativa a este tipo de ensayos clínicos. Este informe potencia la transparencia, terminando con el oscurantismo imperante en las actividades de las empresas farmacéuticas. Es por esto por lo que he decidido votar a favor del mismo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-273"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96670.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Louis Michel (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Rendre plus transparents, plus clairs et plus uniformes les essais cliniques de médicaments à usage humain est une nécessité vitale pour le bon fonctionnement du système de santé au niveau européen. De par cette transparence, clarté et uniformité des règles en la matière, les patients seront mieux protégés et ils pourront bénéficier de traitements adéquats. En effet, la coordination et l'application cohérente des politiques au niveau local est un des défis majeurs auxquels fait face l'Union européenne. J'encourage les démarches visant à l'harmonisation et la coordination cohérente des politiques au niveau de l'Union. </p>
<p class="contents">En outre, travailler à l'échelle européenne, dans le domaine de la santé, permettra de réduire le coût et la charge de la réalisation d'essais cliniques transnationaux. Je me réjouis de l'avancement scientifique que la proposition va susciter.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-867"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marlene Mizzi (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I supported this report which proposes upgrading existing legislation on clinical trials. Simplifying the EUʼs rules on running clinical trials will improve patient safety and constitute a huge step forward for transparency in clinical trials. The upgrading of the existing legislation will be beneficial for attracting clinical research and boosting Europeʼs competitiveness and innovation capacity.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-876"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96695.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Radvilė Morkūnaitė-Mikulėnienė (PPE), </span></span>  <span class="italic">raštu</span><span class="bold">. -</span> Palaikau šį pranešimą. Siekdami, jog ES išliktų konkurencinga klinikinių tyrimų srityje, turime išsaugoti aukštus standartus ir skatinti naujausių mokslinių tyrimų taikymą šioje srityje. Kartu džiaugiuosi, jog pranešime numatomomis priemonėmis siekiama mažinti biurokratinę naštą, be to, numatoma kurti nacionalines žalos atlyginimo sistemas, kurios skatins tirti retas ligas. Klinikiniai tyrimai yra ta sritis, kurioje turime siekti skaidrumo ir aiškumo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-886"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1318.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">James Nicholson (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I voted in favour of clinical trials reform due to my concerns with the current lack of transparency in the clinical trials process, which the proposals sought to address. Many details of clinical trials process are not published, while information about unsuccessful trials is rarer still. These proposals will ensure that pharmaceutical companies and academic researchers will have to post the results of all their trials in a publicly-accessible database. This is simply good practice in the medical industry and will certainly increase trust amongst patients. I support streamlining the rules on clinical trials across Europe in order to improve the alarming decline of trials conducted in the EU between 2007 and 2011 (25[nbsp ]% decrease). I am also in favour of facilitating increasing numbers of cross-border clinical trials and ensuring a minimum standard of patient safety. Cross-border trials harness the potential to boost efforts in the fight against rare diseases – in Northern Ireland more than one in five patients diagnosed with cancer have participated in clinical trials (6[nbsp ]400 between April 2008 and September 2013). Through collaborative efforts in other regions and Member States, we will hopefully begin to see the development of new disease prevention, diagnosis and treatment.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-896"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96948.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gilles Pargneaux (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur de ce règlement qui vise à redynamiser la recherche clinique en Europe en facilitant la mise en œuvre des essais multinationaux via une harmonisation des processus et une coordination des mécanismes d'évaluation. Dans le cadre des négociations en trilogue, le Parlement européen est parvenu à remettre le patient au centre de ce règlement. Nous avons apporté de réelles améliorations au texte parmi lesquelles: la garantie de transparence du déroulement et des résultats des essais cliniques par la création d'un portail internet de l'Union européenne, la bonne information des patients notamment sur les risques potentiels de l'essai clinique et l'augmentation des mesures de protection pour les personnes vulnérables (enfants, personnes âgées, femmes enceintes, personnes invalides).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-683"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96902.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria do Céu Patrão Neves (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Por nada ter a opor a dar quitação ao Diretor da Agência Europeia de Cooperação dos Reguladores da Energia pela execução do orçamento da Agência para o exercício de 2012, votei favoravelmente o presente relatório.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-046"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36392.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Aldo Patriciello (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> La direttiva 2001/20/CE ha segnato una svolta importante nello sviluppo delle norme per lo svolgimento della sperimentazione clinica nell'Unione e a livello internazionale. Sembra però che tale direttiva abbia creato difficoltà nella promozione della sperimentazione clinica in diversi Stati membri. La proposta di regolamento è volta a garantire nell'Unione un'armonizzazione del quadro giuridico esistente, una riduzione dei tempi di approvazione (approvazione tacita) e una riduzione della burocrazia, ma al contempo la ricerca scientifica e l'innovazione. Considerando, inoltre, che la Commissione suggerisce l'istituzione di una banca dati UE sulle sperimentazioni cliniche che sia pubblicamente accessibile (trasparenza dei risultati), con la relazione sullo studio clinico, sanzioni per i ritardi nella presentazione e la conservazione a tempo indeterminato del fascicolo permanente, ho espresso il mio voto favorevole alla proposta.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-472"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112744.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tonino Picula (S&amp;D), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Klinička ispitivanja su znanstveno medicinska ispitivanja koja se provode na zdravim ili bolesnim ispitanicima koji su dobrovoljno dali pristanak za sudjelovanje. Ona su od iznimne važnosti za medicinu te predstavljaju neizostavan element za napredak na područjima suvremene medicine, liječenja bolesti i zdravstvene skrbi te zbog toga podržavam ovo izvješće. Upravo zbog važnosti kliničkih ispitivanja, zabrinjavajuća je činjenica o padu broja ispitivanja tijekom posljednjih godina i direktnim negativnim posljedicama koje slijede. Za to su, između ostalog, odgovorne neke od mjera u direktivi vezanoj za navedena ispitivanja. Zato su mnogi mišljenja da na tom području treba revidirati sadašnje zakonodavstvo. Također, slažem se da je potrebno smanjiti birokraciju što znači da će biti dovoljan jedan zahtjev za odobrenje neovisno o tome u kojoj državi članici će se ispitivanje izvršiti. Važno je napomenuti da je jedan od trenutačnih najvećih problema manjak transparentnosti, te pozivam na provođenje mjera kako bi se ista povećala. U Hrvatskoj sva klinička ispitivanja odobrava Ministarstvo zdravstva i socijalne skrbi Republike Hrvatske. Prethodno je potrebno pozitivno mišljenje Središnjeg etičkog povjerenstva za klinička ispitivanja lijekova i medicinskih poslova koje se sastoji od zdravstvenih radnika raznih medicinskih specijalnosti kao i osoba koje nisu medicinske struke, to jest pravnici, predstavnici bolesnika itd.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-898"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28409.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Raül Romeva i Rueda (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> In favour. We concentrated our work on transparency and the role of the Ethics Committee. There was a huge campaign from civil society for transparency of clinical trial data. On the other hand, the pharmaceutical industry wanted to subject such data to their very far-ranging understanding of what would be commercially confidential. We not only called strongly for the clinical study report to be uploaded into the EU database, but were also the driving force behind ensuring also that the law explicitly specifies that clinical study reports should not be considered commercially confidential. This would not have happened without us, this is a clear victory for us. We were also keen to re-introduce an Ethics Committee, and requiring a positive opinion by them to allow a trial to go ahead.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-902"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97196.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Oreste Rossi (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Condivido in via generale una distinzione delle sperimentazioni cliniche in tre categorie, come da raccomandazione dell'OCSE: sperimentazioni cliniche, sperimentazioni cliniche a basso rischio e sperimentazioni cliniche a medio rischio. Ho votato a favore del testo frutto di un accordo che mi vede favorevole in particolare alle disposizioni per sperimentazioni cliniche in situazioni d'emergenza autorizzate quando risulti impossibile ottenere il consenso del soggetto o dei suoi rappresentanti entro il periodo di svolgimento della terapia e, inoltre, qualora la sperimentazione sia specificamente progettata per la situazione d'emergenza. La sperimentazione deve rappresentare, per un paziente nella situazione oggetto di prova, un rischio proporzionato a paragone di un trattamento standard; inoltre, essa deve avere la potenzialità di generare un beneficio clinico diretto. Ritengo inoltre fondamentale la difesa dei diritti dei pazienti e dei soggetti vulnerabili, al consenso informato. La partecipazione di taluni gruppi di pazienti, quali i minorenni o le donne incinte, a una sperimentazione clinica deve imporre il soddisfacimento di rigorose condizioni, al fine di garantire un livello di protezione elevato.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-685"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4345.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tokia Saïfi (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> 4[nbsp ]400 demandes d'autorisation relatives à des essais cliniques sont déposées chaque année dans l'Union européenne et l'Espace économique européen. La directive actuelle devrait être remplacée par un règlement afin d'harmoniser les règles et d'établir une collaboration entre les États membres. Grâce à cette harmonisation des règles, les chercheurs européens connaîtront une procédure d'autorisation claire et centralisée avec des délais d'approbation réduits et un processus plus rapide et simplifié au final. </p>
<p class="contents">En parallèle, le texte renforce la transparence des essais cliniques avec la mise à disposition publique d'une base européenne de données pour obtenir des informations concernant les essais cliniques autorisés dans l'Union européenne, que leurs résultats soient positifs ou négatifs. C'est en ce sens que j'ai soutenu ce rapport qui permettra de développer une recherche clinique européenne plus transparente et compétitive.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-360"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/111018.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Salvador Sedó i Alabart (PPE), </span></span>  <span class="italic">por escrito</span><span class="bold">. -</span> Este tipo de ensayos tienen por objetivo final el poder concentrar recursos y esfuerzos de manera altamente eficiente en el desarrollo de tratamientos especiales para las llamadas enfermedades raras, de tan necesaria atención. Mediante esta norma se va a poder facilitar la cooperación transfronteriza para realizar tales ensayos clínicos, de mayor tamaño, más viables y fiables al mismo tiempo. Además, la transparencia en este ámbito va a aumentar gracias a la publicación de dichos ensayos en una base de datos pública que se creará <span class="italic">ad hoc</span>. Todo ello simplificará los procedimientos existentes, al establecerse un marco uniforme en todos los Estados miembros con las correspondientes sanciones para aquellos responsables, tanto investigadores como empresas farmacéuticas, que no se atengan a la regulación aquí aprobada.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-036"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Vi è un ampio consenso sulla necessità di riformare la legislazione vigente in materia di sperimentazioni cliniche, sperimentazioni che sono calate a causa di alcuni dei provvedimenti della direttiva in materia di sperimentazioni cliniche. Concordo nel dire che uno dei problemi principali della direttiva riguarda la sua stessa forma giuridica, che dovrebbe essere sostituita con un regolamento, al fine di garantire maggiore coerenza nell'applicazione. Oltre a ciò, lo snellimento delle procedure burocratiche può giocare un ruolo chiave nel promuovere la sperimentazione in Europa. Ritengo inoltre che la questione dei comitati etici sia di fondamentale importanza, in quanto essi hanno un ruolo importante da svolgere nell'autorizzazione delle sperimentazioni e per garantire la sicurezza e il benessere dei pazienti. L'istituzione di una piattaforma comune europea in cui i comitati etici possano discutere delle modalità di autorizzazione delle sperimentazioni cliniche è quindi molto ben accetta. In ultimo, ritengo che la mancanza di trasparenza dei risultati delle sperimentazioni cliniche sia alla base della perdita di fiducia in esse da parte dei cittadini. A tal proposito, occorre dunque migliorare questo aspetto, favorendo la pubblicazione dei risultati delle sperimentazioni e la pubblicazione di una relazione completa sullo studio clinico nella banca dati UE.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-579"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96920.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kay Swinburne (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I welcome the agreement that has been reached between the institutions on this long-awaited legislation on the clinical trial procedures required before introducing a new medicine to the market. The agreement reached has increased transparency throughout the whole process, which is key to improving public health and advancing science and medicine. I voted in favour of this agreement on the Regulation on clinical trials today as the end report appears balanced and will encourage the adoption of best practice in clinical trials across the EU and beyond.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-670"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> De l'avis général des parties prenantes, il y a lieu de réviser d'urgence la législation en vigueur relative aux essais cliniques. Le nombre d'essais cliniques conduits en Europe a fortement diminué ces dernières années à cause, du moins en partie, de certaines des mesures introduites par la directive sur les essais cliniques. Entre 2007 et 2011, le nombre d'essais cliniques réalisés au sein de l'Union européenne a chuté de 25[nbsp ]% et bon nombre d'essais sont désormais effectués dans des économies émergentes. Cette diminution a non seulement de graves conséquences économiques, mais elle entrave également les avancées médicales, au détriment des patients. </p>
<p class="contents">L'Europe doit être compétitive et attirer les entreprises pharmaceutiques qui souhaitent effectuer des travaux de recherche, mais elle doit en même temps favoriser la recherche universitaire et encourager le développement de médicaments qui visent à traiter les maladies rares. Parallèlement, l'Europe devrait être une référence mondiale en ce qui concerne la sécurité des patients et la transparence, afin de gagner la confiance du public et de promouvoir la qualité de la science.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-742"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Silvia-Adriana Ţicău (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Am votat pentru propunerea de regulament al Parlamentului European și al Consiliului privind testele clinice cu medicamente de uz uman și de abrogare a Directivei 2001/20/CE. Prezentul regulament se aplică tuturor studiilor clinice intervenționale efectuate în Uniune. Un studiu clinic intervențional poate fi efectuat numai dacă drepturile, siguranța, demnitatea și bunăstarea subiecților sunt protejate și au prioritate față de toate celelalte interese și dacă este conceput să genereze date fiabile și solide. </p>
<p class="contents">Studiile clinice intervenționale fac obiectul unor analize științifice și etice și sunt autorizate în conformitate cu prezentul regulament. Analiza etică se efectuează de către o comisie de etică, în conformitate cu dreptul statului membru în cauză. Statele membre se asigură că termenele și procedurile pentru analiza făcută de către comisiile de etică sunt compatibile cu termenele și procedurile prevăzute în prezentul regulament pentru evaluarea cererii de autorizare a unui studiu clinic intervențional.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-762"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119431.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ruža Tomašić (ECR), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Cilj Direktive 2001/20/EZ bilo je pojednostavljenje i ujednačavanje administrativnih odredbi o kliničkim ispitivanjima u Europskoj uniji. Međutim, iskustvo pokazuje da je usklađeni pristup uređivanju kliničkih ispitivanja samo djelomično postignut. Zbog toga je posebno teško izvesti kliničko ispitivanje u nekoliko država članica. Sukladno tome, podržavam stavljanje izvan snage Direktive 2001/20/EZ. </p>
<p class="contents">Novi postupci za odobravanje kliničkih ispitivanja trebali bi stimulirati uključivanje više država članica. Stoga, kako bi se postupci pojednostavnili, treba izbjeći mnogostruko podnošenje uglavnom identičnih informacija i zamijeniti ga podnošenjem jednog dosjea s dokumentacijom vezanom uz zahtjev preko jedinstvenog portala za sve dotične države članice. Portalom bi se trebala smanjiti nepotrebna birokracija kako bi od njega imala korist i javna tijela, a ne samo naručitelji ispitivanja i akademski istraživači koji obavljaju multinacionalna istraživanja.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-783"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96918.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Derek Vaughan (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I was delighted to support this excellent report, which endorsed a wide-ranging package of measures to give hope to patients suffering from rare diseases. The deal reached will make trials more transparent and it will also boost the number of skilled research jobs throughout Europe. This is another positive step in ensuring that researchers throughout the EU work together to reduce the huge cost and burden of conducting trials and hopefully it will bring benefits to many Welsh citizens suffering from rare diseases.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
